Bexobrutideg: A Selective, Catalytic Degrader of Bruton's Tyrosine Kinase Overcomes Inhibitor Resistance and Suppresses Autoantibody-Mediated Disease
Noviski, M.; Auger, P.; Bautista, D.; Brathaban, N.; Bravo, B.; Cass, R.; Cherala, G.; Fung, T. C.; Gajewski, S.; Haria, D.; Jiang, Z.; Karr, D.; Kelly, A.; Kato, D.; Konst, Z. A.; Kumar, A.; Lavarias, M.; Ma, J.; Marchioni, F.; McIntosh, J.; McKinnell, J.; Mihalic, J. T.; Mukerji, R.; Murphy, B.; Narasappa, N.; Peng, G.; Reddy, P. J.; Robbins, D. W.; Rountree, R.; Singh, S.; Tan, Y. S.; Tenn-McClellan, A.; Weiss, D. R.; Wu, J.; Ye, J.; Yung, S.; Messmer, D.; Guiducci, C.; Sands, A. T.; Hansen, G. M.; Cohen, F.
Show abstract
Brutons tyrosine kinase (BTK) transduces B-cell receptor (BCR), Toll-like receptor (TLR), and Fc receptor (FcR) signaling, and overactivation of these pathways drives B-cell malignancies and antibody-mediated autoimmune disease. Small molecule inhibitors block the enzymatic functions of BTK, but this inhibition is undermined by resistance mutations, several of which abolish BTKs kinase activity yet promote oncogenic signaling through BTK scaffolding functions. We report the discovery and characterization of bexobrutideg (NX-5948), a heterobifunctional degrader that recruits cereblon (CRBN) to selectively degrade BTK while sparing molecular glue neosubstrates. We demonstrate that bexobrutideg acts catalytically, degrading thousands of copies of BTK per molecule per hour, and this event-driven pharmacology renders it resilient to mutations that confer resistance to both covalent- and noncovalent-inhibitors. Bexobrutideg is orally bioavailable, driving deep and durable BTK degradation across species. Bexobrutideg demonstrates strong efficacy in wild-type and ibrutinib-resistant lymphoma models and robustly suppresses pathway activation in models of autoimmune disease.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron 93%
- New inhibitors of Mycobacterium tuberculosis identified using systems chemical biology 93%
- Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals 93%
Similar papers in this journal
Similar papers in this journal
- Epitope Engineered Human Haematopoietic Stem Cells are Shielded from CD123-targeted Immunotherapy 92%
- Exploiting KRAS-driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC) 92%
- A stem-loop RNA RIG-I agonist confers prophylactic and therapeutic protection against acute and chronic SARS-CoV-2 infection in mice 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.